Historical Valuation
IO Biotech Inc (IOBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.41. The fair price of IO Biotech Inc (IOBT) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.56
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
IO Biotech Inc (IOBT) has a current Price-to-Book (P/B) ratio of 51.34. Compared to its 3-year average P/B ratio of 11.33 , the current P/B ratio is approximately 353.24% higher. Relative to its 5-year average P/B ratio of 8.28, the current P/B ratio is about 519.93% higher. IO Biotech Inc (IOBT) has a Forward Free Cash Flow (FCF) yield of approximately -167.89%. Compared to its 3-year average FCF yield of -102.10%, the current FCF yield is approximately 64.44% lower. Relative to its 5-year average FCF yield of -86.41% , the current FCF yield is about 94.30% lower.
P/B
Median3y
11.33
Median5y
8.28
FCF Yield
Median3y
-102.10
Median5y
-86.41
Competitors Valuation Multiple
AI Analysis for IOBT
The average P/S ratio for IOBT competitors is 7.86, providing a benchmark for relative valuation. IO Biotech Inc Corp (IOBT.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IOBT
1Y
3Y
5Y
Market capitalization of IOBT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IOBT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IOBT currently overvalued or undervalued?
IO Biotech Inc (IOBT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.41. The fair price of IO Biotech Inc (IOBT) is between to according to relative valuation methord.
What is IO Biotech Inc (IOBT) fair value?
IOBT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IO Biotech Inc (IOBT) is between to according to relative valuation methord.
How does IOBT's valuation metrics compare to the industry average?
The average P/S ratio for IOBT's competitors is 7.86, providing a benchmark for relative valuation. IO Biotech Inc Corp (IOBT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for IO Biotech Inc (IOBT) as of Jan 10 2026?
As of Jan 10 2026, IO Biotech Inc (IOBT) has a P/B ratio of 51.34. This indicates that the market values IOBT at 51.34 times its book value.
What is the current FCF Yield for IO Biotech Inc (IOBT) as of Jan 10 2026?
As of Jan 10 2026, IO Biotech Inc (IOBT) has a FCF Yield of -167.89%. This means that for every dollar of IO Biotech Inc’s market capitalization, the company generates -167.89 cents in free cash flow.
What is the current Forward P/E ratio for IO Biotech Inc (IOBT) as of Jan 10 2026?
As of Jan 10 2026, IO Biotech Inc (IOBT) has a Forward P/E ratio of -1.19. This means the market is willing to pay $-1.19 for every dollar of IO Biotech Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for IO Biotech Inc (IOBT) as of Jan 10 2026?
As of Jan 10 2026, IO Biotech Inc (IOBT) has a Forward P/S ratio of 0.00. This means the market is valuing IOBT at $0.00 for every dollar of expected revenue over the next 12 months.